Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name SL-701
Trade Name
Drug Descriptions

SL-701is an immunotherapy that stimulates anti-tumor immune responses against tumor expressing IL13 receptor alpha-2, EphrinA2 and Survivin (J Clin Oncol 36, 2018 (suppl; abstr 2058)).

CAS Registry Number NA
NCIT ID C114496


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Bevacizumab + SL-701 Bevacizumab SL-701 0 0
SL-701 SL-701 0 1

Additional content available in CKB BOOST